WuXi XDC Cayman Inc.

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E. Other stock markets 12/12/2025			5-day change	1st Jan Change
66.30 ^HKD	-6.09%		-1.78%	+116.31%

11-28	Nomura Adjusts WuXi XDC Cayman's Price Target to HK$82.72 From HK$73.70, Keeps at Buy	MT
11-17	600,000,000 Shares of WuXi XDC Cayman Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025.	CI

600,000,000 Shares of WuXi XDC Cayman Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025.

Published on 11/17/2025 at 12:21 am GMT

S&P Capital IQ

WuXi XDC Cayman Inc.

-6.09%

600,000,000 Shares of WuXi XDC Cayman Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025. These Shares will be under lockup for 732 days starting from 15-NOV-2023 to 16-NOV-2025.

Details:
The shareholders has agreed for a lock-up of 6 months and 12 months from the listing date.

Latest news about WuXi XDC Cayman Inc.

11-28	Nomura Adjusts WuXi XDC Cayman's Price Target to HK$82.72 From HK$73.70, Keeps at Buy	MT
11-17	600,000,000 Shares of WuXi XDC Cayman Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025.	CI
10-23	WuXi XDC Completes HK$1.4 Billion Share Sale to WuXi Biologics	MT
10-10	WuXi AppTec Offloads Further Stake in WuXi XDC Cayman	MT
09-23	WuXi XDC Cayman Revises Caps, Renews Service Agreements With WuXi Biologics	MT
09-03	Hong Kong Stocks Extend Losses on Tariff Concerns; WuXi XDC Gains on Fundraising Plans	MT
09-03	WuXi XDC Renews Services Deal With WuXi AppTec With Revised Cap; Shares Rise 2%	MT
09-03	WuXi XDC to Raise HK$1.4 Billion Through Share Sale to WuXi Biologics	MT
09-03	WuXi XDC to Raise HK$1.3 Billion via Share Placement	MT
09-03	Wuxi XDC Cayman announces placing of up to 22.3 million shares	RE
09-03	Wuxi Xdc Cayman to issue 24.1 million shares	RE
09-01	CMB International Starts WuXi XDC Cayman at Buy with HK$74 Price Target	MT
08-21	Jefferies Adjusts WuXi XDC Cayman's Price Target to HK$80 From HK$60, Keeps at Buy	MT
08-19	Nomura Adjusts WuXi XDC Cayman's Price Target to HK$73.70 From HK$56.55, Keeps at Buy	MT
08-19	WuXi XDC Cayman's H1 Attributable Profit Surges; Revenue Tops Estimates, EPS Misses	MT
08-18	Wuxi XDC Cayman says capital payment is expected to be RMB1,560 million in 2025	RE
08-18	WuXi XDC Cayman Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08-18	Wuxi Xdc Cayman posts HY net profit attributable RMB745.7 million	RE
08-05	Wuxi Xdc Cayman Inc. Achieves Gmp Release of Newly Launched Dp3 Facility At Wuxi Site, Scaling Further Drug Product Manufacturing Capacity	CI
07-23	WuXi XDC Expects Over 50% H1 Profit Growth; Shares Rise 11%	MT
07-23	Wuxi XDC Cayman expects over 67% increase in adjusted net profit in HY	RE
07-23	WuXi XDC Cayman Inc. Provides Earning Guidance for the Six Months Ended June 30, 2025	CI
07-16	Nomura Adjusts WuXi XDC Cayman's Price Target to HK$56.55 From HK$49.76, Keeps at Buy	MT
07-10	WuXi AppTec to More than Double H1 Profit	MT
07-01	WuXi XDC Cayman Inc. Announces the Mechanical Completion of Its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing	CI

Chart WuXi XDC Cayman Inc.

Duration

Period

2268: Dynamic Chart

Company Profile

WuXi XDC Cayman Inc is an investment holding company principally engaged in the provision of comprehensive contract research, development and manufacturing organization (CRDMO) services for antibody drug conjugate (ADC) and other bioconjugates. The Company's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The Company provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The Company principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.

Employees

2,270

Sector

Pharmaceuticals

Calendar

03-30 - Q4 2025 Earnings Release (Projected)

More about the company